Literature DB >> 25207150

The Effects of Local Anaesthetics on QT Parameters during Thoracic Epidural Anaesthesia Combined with General Anaesthesia: Ropivacaine versus Bupivacaine.

Ozlem Güven1, Hilal Sazak1, Ali Alagöz1, Eser Savkılıoğlu1, Cilsem Sevgen Demirbaş1, Ali Yıldız2, Erdem Karabulut3.   

Abstract

BACKGROUND: Many studies focusing on the effects of local anaesthetics on QT intervals have been performed, but the articles evaluating the relationship between thoracic epidural anaesthesia combined with general anaesthesia and QT parameters are very limited. AIMS: We aimed to compare the effects of bupivacaine and ropivacaine on QT interval, corrected QT, dispersion of QT, and corrected dispersion of QT in patients undergoing lung resection under thoracic epidural anaesthesia combined with general anaesthesia. STUDY
DESIGN: Prospective clinical study.
METHODS: Thirty ASA physical status 1-3 patients requiring thoracic epidural anaesthesia combined with general anaesthesia for thoracic surgery. Patients were randomly assigned to two groups, which were allocated to receive either bupivacaine (Group B) or ropivacaine (Group R) during thoracic epidural anaesthesia. Following haemodynamic monitoring, a thoracic epidural catheter was inserted. Local anaesthetic at an average dose of 1.5 mL/ segment was given through an epidural catheter. The same general anaesthesia protocol was administered in both groups. Records and measurements were performed on 10 phases that were between the thoracic epidural catheter insertion to the 5(th) min of endobronchial intubation. In all phases, systolic arterial pressure, diastolic arterial pressure, mean arterial pressure, heart rate, peripheral O2 saturation, and electrocardiogram monitoring were performed in patients. All QT parameters were recorded by 12-lead electrocardiogram and analysed manually by a cardiologist.
RESULTS: QT intervals were similar between two groups. In Group R, corrected QT values at the 20(th) min of local anaesthetic injection and the 5(th) min of endobronchial intubation were shorter than those in Group B (p<0.05). The basal dispersion of QT and dispersion of QT values at the 1(st) min of propofol injection were shorter than those in Group R (p<0.05). The corrected dispersion of QT value at the 1(st) min of propofol injection was shorter in Group R (p<0.05). In Group R, the decrease in mean arterial pressure at the 1st min of fentanyl injection was significant compared with Group B (p<0.05). There was no significant difference between the groups with respect to heart rate and complications.
CONCLUSION: The corrected QT, dispersion of QT, and corrected dispersion of QT intervals were slightly longer in the patients receiving bupivacaine compared with those receiving ropivacaine in various phases of the present study.

Entities:  

Keywords:  Bupivacaine; QT parameters; local anaesthetics; ropivacaine; thoracic epidural anaesthesia

Year:  2013        PMID: 25207150      PMCID: PMC4115939          DOI: 10.5152/balkanmedj.2013.9275

Source DB:  PubMed          Journal:  Balkan Med J        ISSN: 2146-3123            Impact factor:   2.021


  23 in total

Review 1.  Electrocardiographic manifestations: electrolyte abnormalities.

Authors:  Deborah B Diercks; George M Shumaik; Richard A Harrigan; William J Brady; Theodore C Chan
Journal:  J Emerg Med       Date:  2004-08       Impact factor: 1.484

2.  Fast track in thoracic anesthesia and surgery.

Authors:  Javier H Campos
Journal:  Curr Opin Anaesthesiol       Date:  2009-02       Impact factor: 2.706

3.  Autonomic nervous system influences on QT interval in normal subjects.

Authors:  Anthony R Magnano; Steve Holleran; Rajasekhar Ramakrishnan; James A Reiffel; Daniel M Bloomfield
Journal:  J Am Coll Cardiol       Date:  2002-06-05       Impact factor: 24.094

4.  QT interval prolongation as predictor of sudden death in patients with myocardial infarction.

Authors:  P J Schwartz; S Wolf
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

5.  Acute toxicity of ropivacaine compared with that of bupivacaine.

Authors:  D B Scott; A Lee; D Fagan; G M Bowler; P Bloomfield; R Lundh
Journal:  Anesth Analg       Date:  1989-11       Impact factor: 5.108

6.  Effect of thoracic epidural anesthesia with different concentrations of ropivacaine on arterial oxygenation during one-lung ventilation.

Authors:  Yajun Xu; Zhiming Tan; Shilai Wang; Haijun Shao; Xuqin Zhu
Journal:  Anesthesiology       Date:  2010-05       Impact factor: 7.892

7.  A comparison of the effects of desflurane, sevoflurane and propofol on QT, QTc, and P dispersion on ECG.

Authors:  Dilek Kazanci; Süheyla Unver; Umit Karadeniz; Döndü Iyican; Senem Koruk; M Birhan Yilmaz; Ozcan Erdemli
Journal:  Ann Card Anaesth       Date:  2009 Jul-Dec

8.  Effects of thoracic epidural analgesia on cardiovascular function and plasma concentration of free fatty acids and catecholamines in the dog.

Authors:  R Hotvedt; E S Platou; H Refsum
Journal:  Acta Anaesthesiol Scand       Date:  1984-04       Impact factor: 2.105

9.  Cardiotoxicity of ropivacaine--a new amide local anaesthetic agent.

Authors:  S Reiz; S Häggmark; G Johansson; S Nath
Journal:  Acta Anaesthesiol Scand       Date:  1989-02       Impact factor: 2.105

10.  Cardiac electrophysiologic properties of bupivacaine and lidocaine compared with those of ropivacaine, a new amide local anesthetic.

Authors:  R Moller; B G Covino
Journal:  Anesthesiology       Date:  1990-02       Impact factor: 7.892

View more
  2 in total

1.  Elective lung resection increases spatial QRS-T angle and QTc interval.

Authors:  Szymon Bialka; Andrzej Jaroszynski; Todd T Schlegel; Hanna Misiolek; Damian Czyzewski; Marek Sawicki; Piotr Skoczylas; Magdalena Bielacz; Mateusz Bialy; Lukasz Szarpak; Wojciech Dabrowski
Journal:  Cardiol J       Date:  2018-12-21       Impact factor: 2.737

2.  Open kidney cancer surgery and perioperative cardiac arrhythmias.

Authors:  Karolina Dobrońska; Lidia Jureczko; Rafał Kowalczyk; Piotr Dobroński; Janusz Trzebicki
Journal:  Cent European J Urol       Date:  2020-11-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.